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Background—Previous studies reveal major differences in the estimated cardiovascular risk in diabetes mellitus, including
uncertainty about the risk in young patients. Therefore, large studies of well-defined populations are needed.
Methods and Results—All residents in Denmark 30 years of age were followed up for 5 years (1997 to 2002) by
individual-level linkage of nationwide registers. Diabetes patients receiving glucose-lowering medications and
nondiabetics with and without a prior myocardial infarction were compared. At baseline, 71 801 (2.2%) had diabetes
mellitus and 79 575 (2.4%) had a prior myocardial infarction. Regardless of age, age-adjusted Cox proportional-hazard
ratios for cardiovascular death were 2.42 (95% confidence interval [CI], 2.35 to 2.49) in men with diabetes mellitus
without a prior myocardial infarction and 2.44 (95% CI, 2.39 to 2.49) in nondiabetic men with a prior myocardial
infarction (P0.60), with nondiabetics without a prior myocardial infarction as the reference. Results for women were
2.45 (95% CI, 2.38 to 2.51) and 2.62 (95% CI, 2.55 to 2.69) (P0.001), respectively. For the composite of myocardial
infarction, stroke, and cardiovascular death, the hazard ratios in men with diabetes only were 2.32 (95% CI, 2.27 to 2.38)
and 2.48 (95% CI, 2.43 to 2.54) in those with a prior myocardial infarction only (P0.001). Results for women were
2.48 (95% CI, 2.43 to 2.54) and 2.71 (95% CI, 2.65 to 2.78) (P0.001), respectively. Risks were similar for both
diabetes types. Analyses with adjustments for comorbidity, socioeconomic status, and prophylactic medical treatment
showed similar results, and propensity score–based matched-pair analyses supported these findings.
Conclusions—Patients requiring glucose-lowering therapy who were 30 years of age exhibited a cardiovascular risk
comparable to nondiabetics with a prior myocardial infarction, regardless of sex and diabetes type. Therefore,
requirement for glucose-lowering therapy should prompt intensive prophylactic treatment for cardiovascular diseases.
(Circulation. 2008;117:1945-1954.)
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It is unclear when primary prevention for cardiovasculardisease (CVD) should be introduced in the treatment of
diabetes mellitus, particular in the case of young individ-
uals with diabetes. Major clinical practice guidelines
feature significant disparities in recommendations for pri-
mary prevention in diabetes mellitus. Several guidelines
recommend target cholesterol levels in type 2 diabetes
mellitus without preexisting CVD similar to the secondary
prevention of patients with established CVD.1– 6 These
recommendations apply to all individuals with type 2
diabetes mellitus regardless of age in some guidelines,4,5
whereas others adopt an age threshold of 40 years1–3 or are
restricted to individual risk assessment.3,6 Similar dispar-
ities are acknowledged in guidelines recommending pri-
mary prevention in patients with type 1 diabetes melli-
tus.2,3,5 Furthermore, current guidelines for antiplatelet
therapy in patients with diabetes feature various age limits
and requirements for additional risk factors to merit
therapy.2,3,5,6 Despite the increasing incidence and decreas-
ing age of onset in diabetes mellitus,7 only a few larger
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studies have considered cardiovascular risk in younger
patients with diabetes mellitus.8 –11
Editorial p 1914
Clinical Perspective p 1954
To obtain accurate estimates for all combinations of sex
and age, we performed a nationwide study of cardiovascular
risk in patients with diabetes requiring glucose-lowering
therapy and compared the risk with that of nondiabetics with
a previous myocardial infarction (MI). The study included the
entire Danish population 30 years of age (3.3 million
individuals).
Methods
Population and Data Sources
Through the Danish Civil Registration system, we identified all
inhabitants in Denmark at least 30 years of age and older and alive
on January 1, 1997. All deaths (including deaths occurring in other
countries) were identified from the Central Population Register, in
which deaths are recorded within 2 weeks. Causes of death were
obtained from the National Causes of Death Register, in which
immediate, contributory, and underlying causes are recorded using
the International Classification of Diseases (ICD). Morbidity was
obtained from the Danish National Patient Register,12 in which
hospital admissions and diagnoses have been recorded since 1978
with ICD codes. All medications dispensed from pharmacies were
obtained from the National Prescription Registry (the Danish Reg-
istry of Medicinal Product Statistics), which has recorded all dis-
pensed prescriptions since 1995. The following ICD-10 codes were
used for end points in this study; MI, I21 to I22 (and ICD-8 code 410
for prior MI before 1994); stroke, I61 to I64; CVDs, I00 to I99; and
coronary heart diseases, I20 to I25 and I46.
Diabetes Mellitus
Patients with diabetes mellitus were identified as individuals claim-
ing at least 1 prescription of glucose-lowering medication (oral or
insulin) in the 6-month period before January 1, 1997. Patients
initiating glucose-lowering agents during the follow-up period were
included in the reference population.
Prior MI
Previous cases of MI were identified as hospitalization with an MI as
the primary or secondary diagnosis in the 19-year period before
inclusion.
Comorbidity
Comorbidity was assessed as the Charlson comorbidity index score
using ICD-10 codes13 or by registration of hospital admittance up to
1 year before the inclusion date of diagnoses listed in Table 1 using
ICD 10 codes.
Medical Treatment
Medical treatment with statins, -blockers, and angiotensin-
converting enzyme inhibitors/angiotensin receptor blockers was
registered as prescription claims up to 6 months before the inclusion
date and during follow-up.
Statistical Analyses
Cox multivariable proportional-hazard regression models were per-
formed to estimate differences among risk groups. All Cox models
were censored for deaths resulting from causes unrelated to the end
point of interest. For combined end points, the time to event was
estimated for the first event. Cox analyses were performed with
adjustment for age and with multivariable adjustment for age, gross
income, comorbidity, and time-dependent adjustment for medical
treatment during follow-up.
Specifically, we used propensity score analysis to identify a set of
cases (subjects with diabetes only) and controls (nondiabetics with a
prior MI) who were matched for age, sex, gross income, comorbidity
(Table 1), and medical treatment up to 6 months before inclusion
date. A propensity score for the likelihood of receiving glucose-
lowering medication was quantified by multivariable logistic regres-
sion. The C statistic was 0.74, indicating a good discriminative
power of the model. A Greedy matching macro (by Lori S. Parsons,
accessed January 1, 2007, at http://www2.sas.com/proceedings/
sugi26/p214–26.pdf) was used to match each case (n64 111) to 1
control. A multivariable-adjusted Cox model was fitted including the
propensity score.
A sensitivity analysis was performed in an age-adjusted Cox
analysis for cardiovascular death comparing patients with new
requirement for glucose-lowering agents in 1997 who survived 30
days with incident first-time MI in 1997 with various survival times
of 30-day intervals. Secular trends for different end points were
obtained by age-adjusted Cox proportional-hazard analyses per-
formed for each year during follow-up.
Model assumptions—linearity of continuous variables, the
proportional-hazard assumption, and lack of interactions—were
tested and found to be valid except when otherwise indicated. Tests
for interactions were performed for age and sex, diabetes mellitus
and a prior MI, diabetes mellitus and sex, diabetes mellitus and age,
a prior MI and sex, and a prior MI and age. All statistical calculations
were performed with the SAS statistical software package for UNIX
servers, version 9.1 (SAS Institute Inc, Cary, NC).
The authors had full access to and take full responsibility for the
integrity of the data. All authors have read and agree to the
manuscript as written.
Results
On January 1, 1997, 3 274 472 individuals 30 years of age
lived in Denmark; of these, 71 801 (2.2%) received glucose-
lowering treatment and were categorized as patients with
diabetes mellitus. Glucose-lowering treatment was oral or
combined oral and insulin in 45 827 (64%) subjects and
insulin only in 25 974 subjects (36%).
Baseline characteristics before inclusion according to risk
groups are summarized in Table 1. Numbers of events during
follow-up according to the groups at risk are summarized in
Table 2; the risk of selected end points is shown in Table 3.
Multivariable analyses revealed no interaction between age
and the different risk groups, whereas significant interactions
(P0.001) were found between sex and diabetes and a prior
MI for most end points; thus, subsequent analyses were
stratified by sex. The magnitudes of sex differences conferred
by a prior MI were more pronounced than those conferred by
diabetes mellitus, particularly for coronary end points.
Cardiovascular Morbidity and Mortality
As shown in Table 3 and Figure 1, cardiovascular death risks
were similar between men without diabetes mellitus but a
prior MI and men with diabetes mellitus but no prior MI
(hazard ratio, 2.44 and 2.42 in the 2 groups, respectively;
P0.60), and in women, cardiovascular death was slightly,
albeit significantly, higher in those without diabetes mellitus
but with a prior MI (hazard ratio, 2.62 and 2.45 in the 2
groups; P0.001; Table 3). Similar results were obtained for
the composite of MI, stroke, or cardiovascular death, al-
though a significant difference was found between the 2
groups (P0.001 for both sexes; Table 3 and Figure 2).
Multivariable adjustment did not change these results, and the
propensity score–based matched-pair analyses supported
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Table 1. Baseline Personal Characteristics Stratified by Sex in Relation to Diabetes Mellitus and a Prior MI
No Diabetes Mellitus
(n3 202 671)
Diabetes Mellitus
(n71 801)
Total
No Prior MI
(n3 129 516)
Prior MI
(n73 155)
No Prior MI
(n65 382)
Prior MI
(n6419) P
Sex, n (%)*
Men 1 582 217 (48.3) 1 494 969 (47.77) 49 357 (67.47) 33 741 (51.61) 4150 (64.65) 0.001
Women 1 692 255 (51.9) 1 634 547 (52.23) 23 798 (32.53) 31 641 (48.39) 2269 (35.35) 0.001
Age, y†
Men 51.314.7 50.014.5 66.511.5 60.414.2 66.511.5 0.001
Women 53.916.2 53.416.1 72.111.7 65.015.1 72.211.7 0.001
Person-years
Men 7 551 639 7 181 806 208 202 146 029 15 602 0.001
Women 8 083 750 7 842 902 96 410 136 285 8153 0.001
Exposure time, y†
Men 4.80.8 4.80.8 4.21.4 4.31.4 3.81.7 0.001
Women 4.80.8 4.80.8 4.11.5 4.31.4 3.61.7 0.001
Comorbidity, n (%)‡
Congestive heart failure
Men 7346 (0.46) 6212 (0.42) 745 (1.51) 309 (0.92) 80 (1.93) 0.001
Women 6729 (0.40) 6052 (0.37) 359 (1.51) 277 (0.88) 41 (1.81) 0.001
Cardiac dysrhythmia
Men 10 255 (0.65) 8994 (0.57) 825 (1.67) 357 (1.06) 79 (1.90) 0.001
Women 9766 (0.58) 8999 (0.53) 377 (1.58) 344 (1.09) 46 (2.03) 0.001
Peripheral vascular disease
Men 6858 (0.43) 5955 (0.40) 525 (1.06) 308 (0.91) 70 (1.69) 0.001
Women 5502 (0.33) 5057 (0.31) 217 (0.91) 211 (0.67) 17 (0.75) 0.001
Cerebrovascular disease
Men 9127 (0.58) 8027 (0.54) 658 (1.33) 368 (1.09) 74 (1.78) 0.001
Women 8681 (0.51) 7997 (0.49) 323 (1.36) 312 (0.99) 49 (2.16) 0.001
Dementia
Men 584 (0.03) 505 (0.03) 44 (0.09) 26 (0.08) 3 (0.07) 0.001
Women 578 (0.04) 529 (0.03 34 (0.14) 18 (0.06) 3 (0.05) 0.001
Chronic pulmonary disease
Men 11 529 (0.73) 10 313 (0.69) 758 (1.54) 406 (1.20) 52 (1.25) 0.001
Women 13 512 (0.80) 12 780 (0.78) 361 (1.52) 342 (1.08) 29 (1.28) 0.001
Peptic ulcer disease
Men 6478 (0.41) 5833 (0.39) 383 (0.78) 232 (0.69) 30 (0.72) 0.001
Women 8595 (0.51) 8055 (0.49) 279 (1.17) 242 (0.76) 19 (0.84) 0.001
Liver disease
Men 1270 (0.08) 1173 (0.08) 50 (0.10) 42 (0.12) 5 (0.12) 0.01
Women 832 (0.05) 808 (0.05) 8 (0.03) 13 (0.04) 3 (0.13) 0.19
Hemiplegia
Men 451 (0.03) 425 (0.03) 14 (0.03) 10 (0.03) 2 (0.05) 0.90
Women 366 (0.02) 351 (0.02) 6 (0.03) 8 (0.03) 1 (0.04) 0.83
Acute renal failure
Men 1128 (0.07) 955 (0.06) 109 (0.22) 60 (0.18) 4 (0.10) 0.001
Women 779 (0.05) 725 (0.04) 27 (0.11) 25 (0.08) 2 (0.09 0.001
Chronic renal failure
Men 190 (0.01) 169 (0.01) 9 (0.02) 9 (0.03) 3 (0.07) 0.001
Women 230 (0.01) 218 (0.01) 9 (0.04) 3 (0.01) 0 0.01
(Continued )
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these findings for men, whereas a slightly lower risk was
obtained in women with diabetes only compared with a prior
MI for both end points (Table 3).
Coronary Morbidity and Mortality
Results for coronary and composite coronary end points
revealed notably higher risks in patients with diabetes only
compared with the reference population, although they were
lower than for a prior MI only (Table 3). At all coronary end
points, women exhibited substantially higher relative risks
than men did (P0.001; Table 3). Results were similar after
multivariable adjustments, whereas in the matched-pair anal-
yses, the differences between the 2 groups were slightly
increased (Table 3).
All-Cause Mortality
All-cause mortality was increased in subjects with diabetes
only compared with those with a prior MI only (Table 3). The
multivariable-adjusted and matched-pair analyses indicated
smaller differences between the 2 risk groups (Table 3).
Women with a prior MI only had a relatively higher risk than
men (P0.001), whereas no sex differences were evident for
patients with diabetes mellitus (P0.09 and P0.45 for sex
differences for diabetic patients without and with a prior MI,
respectively; the corresponding multivariable-adjusted values
were P0.99 and P0.07).
Other End Points
Patients with diabetes mellitus exhibited an increased risk of
stroke (fatal and nonfatal) relative to nondiabetics with prior MI
(Table 3), although this difference was eliminated for women in
the matched-pair analyses (Table 3). No sex differences were
demonstrated in patients with diabetes mellitus.
Diabetes Mellitus and Prior MI
Patients with both diabetes and a prior MI generally had more
comorbidity (Table 1) and demonstrated additive and very
high risks at all end points except stroke (Table 3).
Type 1 and Type 2 Diabetes Mellitus
Patients 40 years of age were subdivided into those receiv-
ing insulin only (defined as type 1 diabetes mellitus) and
Table 1. Continued
No Diabetes Mellitus
(n3 202 671)
Diabetes Mellitus
(n71 801)
Total
No Prior MI
(n3 129 516)
Prior MI
(n73 155)
No Prior MI
(n65 382)
Prior MI
(n6419) P
Pulmonary edema
Men 7026 (0.44) 6201 (0.41) 521 (1.06) 255 (0.76) 49 (1.18) 0.001
Women 7384 (0.44) 6846 (0.42) 287 (1.21) 227 (0.72) 24 (1.06) 0.001
Shock
Men 699 (0.04) 607 (0.04) 55 (0.11) 30 (0.09) 7 (0.17) 0.001
Women 748 (0.04) 688 (0.04) 23 (0.10) 31 (0.10) 6 (0.26) 0.001
Malignancy
Men 16 991 (1.07) 15 186 (1.02) 1117 (2.26) 585 (1.73) 103 (2.48) 0.001
Women 23 048 (1.36) 21 794 (1.33) 556 (2.34) 635 (2.01) 63 (2.78) 0.001
Charlson index†
Men 0.06 (0.37) 0.05 (0.34) 0.20 (0.61) 0.16 (0.57) 0.31 (0.69) 0.001
Women 0.06 (0.36) 0.05 (0.35) 0.21 (0.62) 0.14 (0.52) 0.31 (0.70) 0.001
Medication before admission,‡ n (%)§
Statins
Men 15 310 (1.0) 7945 (0.5) 6351 (12.9) 554 (1.6) 460 (11.1) 0.001
Women 10 396 (0.6) 7318 (0.5) 2361 (9.9) 511 (1.6) 206 (9.1) 0.001
-Blockers
Men 59 014 (3.7) 43 722 (2.9) 12 191 (24.7) 2134 (6.3) 967 (23.3) 0.001
Women 81 258 (4.8) 72 477 (4.4) 5561 (23.4) 2702 (8.5) 518 (22.8) 0.001
ACE inhibitors/ARBs
Men 63 296 (4.0) 44 488 (3.0) 9822 (19.9) 7374 (21.9) 1612 (38.8) 0.001
Women 60 948 (3.6) 49 477 (3.0) 4355 (18.3) 6272 (19.8) 844 (37.2) 0.001
ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blockers.
*In percentages of the respective risk group (eg, number of men with diabetes mellitus and prior MI in percentage of all patients with diabetes mellitus and
prior MI).
†MeanSD.
‡In percentages of the respective risk group (eg, numbers of men with diabetes and prior MI with congestive heart failure in percentage of all men with diabetes
and prior MI).
§Medical treatment registered up to 6 months before inclusion date.
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those receiving oral glucose-lowering agents only or in
combination with insulin (type 2 diabetes mellitus). No
important interactions were evident between type 1 and type
2 diabetes at all end points explored; therefore, type 1 and
type 2 patients expressed the same risk.
Furthermore, all analyses were repeated in patients with
type 2 diabetes only at all ages by the exclusion of patients
receiving insulin-only treatment. Results similar to those for
the total diabetes population were demonstrated.
Supplementary Analyses
All analyses were repeated with a prior MI defined as the
occurrence of an MI within 5 years before inclusion, which
was taken to be a recent MI. At all end points, results were
similar to those presented. Furthermore, patients with a new
requirement for glucose-lowering agents exhibited a risk of
cardiovascular death similar to that of patients with incident
MI who had survived 180 days (men) or 330 days (women).
Secular changes were demonstrated in medical treatment
during follow-up (Figure 3). For most end points, patients
with a prior MI experienced a decrease in risk from 1997 to
2001, whereas the risks for patients with diabetes only were
unchanged during follow-up (Figure 4).
Discussion
The major finding of this study is that all patients requiring
glucose-lowering treatment who are 30 years of age are at
a particularly high risk of cardiovascular mortality and
morbidity, comparable to that of nondiabetics with a prior
MI, regardless of sex and diabetes type.
Previous reports have documented that patients requiring
glucose-lowering agents with or without prior CVD exhibit a
particularly high risk.14,15 Compared with our study, most
previous reports on larger populations included both patients
on glucose-lowering medication and those on dietary-only
treatment8,9,14,16–18 and revealed a generally lower diabetes-
related cardiovascular risk relative to patients with prior
CVD.8,14,16–18
Consistent with our results, a Finnish study of middle-aged
patients19,20 and the Multiple Risk Factor Intervention Trial
(MRFIT) of men 35 to 57 years of age14 demonstrated that
patients with diabetes receiving glucose-lowering agents had
a risk of cardiovascular and all-cause mortality similar to that
of patients with prior MI or CVD, respectively. We found a
substantially increased risk of MI and coronary death in
patients with diabetes only, although the risk was slightly
lower than for patients with a prior MI only. Our results were
corroborated by the MRFIT study,21 whereas the magnitude
of coronary death was similar for diabetes only and a prior MI
only in the Finnish population.19,20
As demonstrated in our study, it was previously shown that
the diabetes-related risk attributable to coronary events is
Table 2. Numbers of Events During the Study Period (1997–2002) for Different End Points Stratified by Sex in Relation
to Diabetes Mellitus and a Prior MI
Events, n (%)*
No Diabetes Mellitus Diabetes Mellitus
No Prior MI Prior MI No Prior MI Prior MI Total
MI (fatal or nonfatal)
Men 32 231 (2.2) 7846 (15.9) 2466 (7.3) 984 (23.7) 71 374 (2.2)
Women 21 787 (1.3) 3325 (14.0) 2168 (6.9) 567 (25.0)
Stroke (fatal or nonfatal)
Men 36 878 (2.5) 3937 (7.8) 3245 (9.6) 544 (27.4) 90 731 (2.8)
Women 40 535 (2.5) 2152 (9.0) 3118 (10.0) 322 (14.2)
Coronary death
Men 24 135 (1.6) 8226 (16.7) 2511 (7.4) 1137 (27.4) 67 816 (2.1)
Women 24 394 (1.5) 4321 (18.2) 2392 (7.6) 700 (30.9)
Cardiovascular death
Men 51 698 (3.5) 9928 (20.1) 4937 (14.6) 1417 (34.1) 139 985 (4.3)
Women 60 311 (3.7) 5842 (24.5) 4950 (15.64) 902 (39.8)
MI or coronary death
Men 44 579 (3.0) 12 461 (25.2) 3735 (11.1) 1583 (38.14) 108 882 (3.3)
Women 36 369 (2.2) 5887 (24.7) 3348 (10.6) 920 (40.5)
MI, stroke, or cardiovascular death
Men 95 603 (6.4) 16 026 (32.5) 7854 (23.3) 2046 (49.3) 233 170 (7.1)
Women 94 922 (5.8) 8190 (34.4) 7332 (23.2) 1197 (52.8)
All-cause mortality
Men 114 931 (7.7) 14 375 (29.1) 8566 (25.4) 1851 (44.6) 287 471 (8.8)
Women 129 844 (7.9) 8393 (35.3) 8365 (26.4) 1146 (50.5)
*In percentages of the respective risk group (eg, number of MI in men with diabetes mellitus and prior MI in percentage of all men with diabetes
mellitus and prior MI).
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higher in women than in men.8 Previous smaller studies
demonstrated that the diabetes-related risk for cardiovascular
death and total death was relatively higher in women than in
men,20,22 whereas almost similar relative risks for the 2 sexes
were demonstrated in our study. Furthermore, because of a
higher impact of a prior MI on sex differences in the
matched-pair analyses, diabetes mellitus conferred a lower
risk in women compared with men relative to their counter-
parts with a prior MI at all end points, whereas women
expressed higher relative risks in other studies.20,22 In agree-
ment with our results was a large Canadian study demonstrat-
ing that the impact of diabetes mellitus was similar in the 2
sexes for total death and further that the impact of a prior MI
was more pronounced than diabetes on sex differences for a
MI.8 Importantly, the studies addressing these issues have
notable differences in age ranges, designs, and definitions of
the study populations that could explain the discrepancies
with our study.
Presumably induced by more baseline comorbidity (Table
1), additive risks were demonstrated for patients with both
diabetes mellitus and a prior MI. These findings are corrob-
orated by several other studies8,9,14,17,18,20 and support the
notion of diabetes mellitus as a cardiovascular risk equivalent
for both men and women.
Another population study demonstrated relatively lower
cardiovascular risk in younger diabetes patients.8 The
inclusion of diabetes patients on dietary-only treatment in
this study could explain the discrepancies with our study.
Indeed, the MRFIT study, which included only patients requir-
ing glucose-lowering agents, confirmed our finding of a high
diabetes-related cardiovascular risk at younger ages.21
A British study reported a markedly elevated risk of
cardiovascular death in patients with type 1 diabetes mellitus
without prior CVD for all ages.11 A smaller study demon-
strated that the increased mortality in patients with type 1
diabetes who were 30 years of age was attributable to
Table 3. Age- and Multivariable-Adjusted Cox Multivariable Proportional-Hazard Analysis Stratified by Sex Demonstrating Relative
Hazards for Different End Points in Relation to Diabetes Mellitus and a Prior MI
Age-Adjusted Analyses Multivariable-Adjusted Analyses*
HR‡ (95% CI) HR‡ (95% CI)
Matched-Pair Sample*†
End Points Prior MI
Diabetes
Mellitus P§
Diabetes Mellitus
and Prior MI Prior MI
Diabetes
Mellitus P§
Diabetes Mellitus
and Prior MI
Diabetes
Mellitus vs Prior
MI, HR (95% CI) P§
MI (fatal or
nonfatal)
Men 3.97 (3.87–4.07) 2.30 (2.21–2.40) 0.001 6.81 (6.40–7.25) 3.01 (2.93–3.09) 1.85 (1.77–1.92) 0.001 4.24 (3.97–4.53) 0.55 (0.53–0.58) 0.001
Women 5.34 (5.15–5.54) 3.32 (3.18–3.47) 0.001 11.48 (10.56–2.47) 4.20 (4.05–4.36) 2.69 (2.57–2.81) 0.001 7.32 (6.72–7.97) 0.52 (0.49–0.54) 0.001
Stroke (fatal
or nonfatal)
Men 1.53 (1.48–1.58) 2.51 (2.43–2.61) 0.001 2.91 (2.67–3.16) 1.16 (1.12–1.20) 1.92 (1.85–1.99) 0.001 1.72 (1.58–1.88) 1.30 (1.23–1.37) 0.001
Women 1.64 (1.57–1.71) 2.45 (2.36-2.54) 0.001 3.08 (2.76–3.43) 1.27 (1.21–1.32) 1.90 (1.83–1.97) 0.001 1.82 (1.63–2.04) 1.01 (0.96–1.06) 0.78
Coronary
death
Men 4.15 (4.04–4.25) 2.61 (2.51–2.72) 0.001 7.90 (7.44–8.38) 3.07 (2.99–3.15) 1.91 (1.84–2.00) 0.001 4.28 (4.02–4.55) 0.75 (0.71–0.79) 0.001
Women 4.61 (4.46-4.76) 2.81 (2.69–2.93) 0.001 9.62 (8.93–10.32) 3.53 (3.41–3.65) 2.09 (2.00–2.18) 0.001 5.18 (4.80–5.60) 0.65 (0.62–0.68) 0.001
Cardiovascular
death
Men 2.44 (2.39–2.49) 2.42 (2.35-2.49) 0.60 4.73 (4.49–0.4.97) 1.77 (1.73–1.81) 1.78 (1.73–1.84) 0.67 2.65 (2.51–2.80) 1.02 (0.98–1.06) 0.44
Women 2.62 (2.55–2.69) 2.45 (2.38–2.51) 0.001 5.23 (4.90–5.57) 1.96 (1.90–2.01) 1.77 (1.71–1.82) 0.001 2.87 (2.68–3.07) 0.72 (0.69–0.74) 0.001
MI or coronary
death
Men 4.05 (3.96–4.13) 2.32 (2.25–2.40) 0.001 7.06 (6.72–7.43) 3.06 (3.00–3.13) 1.78 (1.72–1.84) 0.001 4.15 (3.94–4.37) 0.63 (0.60–0.65) 0.001
Women 5.01 (4.87–5.15) 2.85 (2.75–2.96) 0.001 9.97 (9.34–10.65) 3.92 (3.81–4.03) 2.22 (2.14–2.30) 0.001 5.94 (5.55–6.35) 0.54 (0.52–0.57) 0.001
MI, stroke, or
CVD Death
Men 2.48 (2.44–2.52) 2.32 (2.27–2.38) 0.005 4.34 (4.25–4.63) 1.84 (1.80–1.87) 1.76 (1.72–1.81) 0.005 2.58 (2.47–2.70) 0.94 (0.91–0.97) 0.001
Women 2.71 (2.65–2.78) 2.48 (2.43–2.54) 0.001 5.13 (4.85–5.43) 2.01 (2.02–2.12) 1.87 (1.83–1.92) 0.001 2.98 (2.82–3.16) 0.69 (0.67–0.71) 0.001
All-cause
mortality
Men 1.63 (1.60–1.66) 1.96 (1.92–2.01) 0.001 2.86 (2.73–2.99) 1.22 (1.20–1.25) 1.33 (1.30–1.36) 0.001 1.39 (1.33–1.46) 1.16 (1.12–1.20) 0.001
Women 1.79 (1.75–1.83) 1.91 (1.87–1.95) 0.001 3.12 (2.94–3.02) 1.31 (1.28–1.34) 1.33 (1.30–1.36) 0.29 1.50 (1.41–1.59) 0.86 (0.84–0.89) 0.001
*Analyses were adjusted for age, comorbidity (in the matched-pair analyses as comorbidity covariates in Table 1; otherwise as the Charlson index), socioeconomic
factors, and time-dependent adjustment for medical treatment with lipid-lowering drugs, -blockers, and angiotensin-converting enzyme inhibitors/angiotensin
receptor blockers during follow-up. HR indicates hazard ratio.
†Propensity score was based on matched-pair analyses.
‡Reference is nondiabetics without a prior MI.
§Probability value for the comparison of diabetes versus a prior MI.
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cardiovascular events.10 In the Diabetes Control and Compli-
cation Trial, excess cardiovascular mortality in patients with
type 1 diabetes mellitus also was evident after adjustment for
diabetic nephropathy.23 These studies are consistent with our
indication of a particularly high cardiovascular risk in pa-
tients with type 1 diabetes mellitus even at younger ages.
By including the entire population of Denmark who were
30 years of age, we avoided any selection bias related to age,
sex, income, willingness to participate, relation to a physician, or
health insurance organizations. The diagnosis of MI in the
National Patient Registry has proved to be valid, with a sensi-
tivity of 91% and a positive predictive value of 93%.24 The
stroke diagnoses chosen for this study in the National Patient
Registry had positive predictive values of 74% to 97%.25
Validation of coronary and cardiovascular events in similar
populations demonstrated acceptable levels of sensitivity, with a
tendency to overestimate cardiovascular deaths, although this
overestimation would occur in all risk groups in our study.26,27
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Figure 1. Event rates for cardiovascular mortality in men (A) and women (B) stratified by age and sex in relation to diabetes mellitus
(DM) and a prior MI.
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Figure 2. Event rates for the composite end point of MI (nonfatal), stroke (nonfatal), and cardiovascular death in men (A) and women
(B) stratified by age in relation to diabetes mellitus (DM) and a prior MI.
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Glucose-lowering medications are dispensed only on prescription in
Denmark, and the National Prescription Register is linked to the
partial reimbursement policy for drug expenses by the national
health security systems and has been shown to be accurate.28
This study also has important limitations that should be
acknowledged. We were unable to study patients on diet-only
treatment, which makes our population similar to that of the
Haffner et al study19 but different from those of several
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Figure 3. Secular trends for medical treatment in percentage during follow-up in relation to diabetes mellitus and a prior MI. ACE indi-
cates angiotensin-converting enzyme; ARB, angiotensin receptor blocker.
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Figure 4. Age-adjusted Cox multivariable proportional-hazard analysis stratified by sex demonstrating secular trends in relative risks
(RR) for different end points in relation to diabetes mellitus and a prior MI, with nondiabetics without a prior MI as the reference.
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others.8,9,14,16–18 Nevertheless, the cardiovascular risk in dia-
betes patients on dietary-only treatment needs attention.
Type 1 and type 2 diabetes mellitus could not be differen-
tiated precisely in our study, although by investigating
patients 40 years of age, we distinguished subgroups with a
high probability of type 1 (insulin-only treatment) and type 2
(tablets) diabetes mellitus. Therefore, type 2 patients receiv-
ing insulin only could be misclassified as type 1, but
presumably this would be a minority in this age group.
Furthermore, in our substudy of patients receiving oral
glucose-lowering medications only, we demonstrated that our
results are applicable to patients with type 2 diabetes mellitus
of all ages and for both sexes. Unfortunately, we were unable
to adjust for well-known risk factors such as hypertension,
lipid disorders, body mass index, smoking, physical activity,
dietary factors, and blood glucose levels in our study.
Although some reports have indicated that the diabetes-
related cardiovascular risk depends on the numbers of preex-
isting risk factors,29 the degree of arteriosclerosis was shown
to be unrelated to the number of risk factors in diabetes
mellitus.30 Analysis of the Framingham population demon-
strated that, independently of other coexisting risk factors,
coronary mortality was influenced by diabetes duration.31 We
were unable to account for diabetes duration, but from
estimates of expected time with diabetes before diagnosis32
and before initiation of glucose-lowering therapy,33 it is
reasonable to assume that diabetes duration in our study was
7 to 10 years, implying a diabetes population at high risk.
Because the study population consisted mainly of whites, the
generalizability of this study to other ethnicities is uncertain.
Conclusions and Clinical Implications
Results of our present study indicate that all patients 30
years of age with diabetes who require glucose-lowering
therapy should also receive intensive primary prevention for
CVD, regardless of other risk factors, sex, or type of diabetes
mellitus. Therefore, when glucose-lowering medications are
required in the treatment of diabetes mellitus, antiplatelet
therapy, statins, and possibly an angiotensin-converting en-
zyme inhibitor/angiotensin receptor blocker should be added
to the treatment because these pharmaceuticals are proven to
be safe and effective in the primary prevention of cardiovas-
cular events in diabetes mellitus.34–36 Further research is
needed to clarify if these diabetic patients profit from the very
low low-density lipoprotein cholesterol goals for MI patients.
Only 38% of patients undergoing treatment with glucose-
lowering agents who have had no prior MI in our country
received treatment with statins in 2004 (T.K.S., unpublished
data, 2007), suggesting that the potential for improving
treatment is substantial.
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CLINICAL PERSPECTIVE
It is widely acknowledged that the presence of diabetes mellitus implies the presence of atherosclerotic cardiovascular
disease. Studies of cardiovascular risk in patients with diabetes mellitus, combined with clinical trials and subgroup
analyses of clinical trials, have resulted in recommendations for treatment with statins, aspirin, and inhibitors of the
renin-angiotensin system for many patients with diabetes mellitus. Guidelines vary considerably, particularly for young
patients with diabetes. The discrepancies between guidelines are driven mainly by the uncertainties of the cardiovascular
risk in diabetes. In the present nationwide study of 3.3 million Danish residents 30 years of age, it was demonstrated that
the risk of cardiovascular death over 5 years was nearly identical in patients with diabetes mellitus requiring
glucose-lowering therapy and in patients with a prior myocardial infarction regardless of age, sex, and type of diabetes.
Similar results were obtained for the combined occurrence of myocardial infarction, stroke, or cardiovascular death,
whereas coronary morbidity/mortality was lower in patients with diabetes mellitus without a prior myocardial infarction
compared with nondiabetics with a prior myocardial infarction. With limited access to controlled trials in patients with
diabetes mellitus, guidelines for prophylactic treatment are currently driven mainly by analyses of cardiovascular risk in
these patients. Specific recommendations on aspirin, statins, and possibly an angiotensin-converting enzyme inhibitor/an-
giotensin receptor blocker depend on randomized controlled trial data. However, our study provides further evidence
supporting the recommendation that all patients 30 years of age with diabetes mellitus who require glucose-lowering
therapy should be considered for aggressive primary prevention interventions.
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